NCT02384954 2024-07-03QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With RituximabAltor BioSciencePhase 1/2 Terminated43 enrolled 15 charts
NCT02890758 2023-02-21Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803Case Comprehensive Cancer CenterPhase 1 Completed14 enrolled